General
Preferred name
lurasidone
Synonyms
Lurasidone HCl ()
SM-13496 Hydrochloride ()
SM-13496 (Hydrochloride)Lurasidone HCl ()
Lurasidone (SM13496) ()
LURASIDONE HYDROCHLORIDE ()
SM-13496 ()
Lurasidone-d8 ()
Latuda ()
Lurasidona ()
SM-13496 FREE BASE ()
Lurasidone (hydrochloride) (CRM) ()
P&D ID
PD009198
CAS
367514-88-3
367514-87-2
1132654-54-6
Tags
available
drug
Approved by
PMDA
FDA
First approval
2010
Drug indication
Schizophrenia
bipolar I disorder
Psychosis
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
57
DESCRIPTION
Lurasidone hydrochloride (Lurasidone HCl) is a thiazole derivative and atypical antipsychotic agent that functions as a dopamine D2 receptor antagonist; serotonin 5-HT2 receptor antagonist, serotonin 5-HT7 receptor antagonist, an antagonist of the adrenergic ??2A and ??2C receptors, as well as a partial serotonin 5-HT1A receptor agonist. It is used in the treatment of schizophrenia and bipolar disorder.
ABSORPTION
Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. ; Bioavailability = 9-19%.
HALF-LIFE
40 mg dose= 18 hours ; 120 mg - 160 mg dose = 29-37 hours
DESCRIPTION
Lurasidone is an atypical antipsychotic with activity at serotonin family receptors that are involved in learning and memory. It is devoid of the anticholinergic effects which are common with most other antipsychotics.
(GtoPdb)
PRICE
52
DESCRIPTION
Lurasidone (SM-13496) is an antagonist of dopamine D2 and 5-HT7 receptors (IC50 = 1.68 and 0.495 nM, respectively) and a partial agonist of the 5-HT1A receptor (IC50 = 6.75 nM).
DESCRIPTION
Lurasidone is an atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I disorder. It binds with high affinity to dopamine-2 receptor.
(Enamine Bioactive Compounds)
DESCRIPTION
Lurasidone hydrochloride (Lurasidone HCl) is a thiazole derivative and atypical antipsychotic agent that functions as a dopamine D2 receptor antagonist; serotonin 5-HT2 receptor antagonist, serotonin 5-HT7 receptor antagonist, an antagonist of the adrenergic α2A and α2C receptors, as well as a partial serotonin 5-HT1A receptor agonist. It is used in the treatment of schizophrenia and bipolar disorder.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
22
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
55
Molecular Weight
492.26
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
7
Aromatic Ring Count
2
cLogP
4.26
TPSA
56.75
Fraction CSP3
0.68
Chiral centers
6.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
5-HT Receptor antagonist
dopamine receptor inhibitor
Norepinephrine inhibitor
dopamine receptor antagonist, serotonin receptor antagonist
Target
Norepinephrine ¦Á2C
ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
5-HT Receptor,Dopamine Receptor
5-HT Receptor
5-HT1A
5-HT2A
5-HT7
D2
dopamine
Norepinephrine α2C
Indication
schizophrenia
Pathway
GPCR/G protein
Neuroscience
Source data
